3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 20...(32466 221874 32521...)

Date:3/11/2009

32,466 221,874 32,521 Operating expenses Research and development costs (22,477) (3,295) 7,469 (2) (15,008) (2,200) Sales, marketing and distribution expenses (119,778) (17,556) 1,000 (1) (118,778) (17,410) General and administrative expenses (31,458) (4,611) 3,097 (1) (28,361) (4,157) Total operating expenses (173,713) (25,462) (162,147) (23,767) Operating income 47,791 7,004 59,727 8,754 Other income/ (expenses), net Interest income 23,953 3,511 23,953 3,511 Grant income 388 57 388 57 Net realized (loss)/gain on available- for-sale securities (18,995) (2,784) 19,144 (3) 149 22 Impairment loss on available- for-sale securities (4,391) (644) 4,391 (4) -- -- Others 1,896 278 1,896 278 Total other Income ,net 2,851 418 26,386 3,868 Income before income tax expense and minority interests 50,642 7,422 86,113 12,622 Income tax expense (11,649) (1,707) -- (5) (11,649) (1,707) Income before minority interests 38,993 5,715 74,464 10,915 Minority interests, net of tax 549 80 549 80 Net income 39,542 5,795 75,013 10,995 Year Ended December 31, 2008 (unaudited), continued Actual Actual Adjustment Adjusted Adjusted
'/>"/>

SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting